Danilo Verge

Dr. Danilo Verge is a distinguished Biotech and Pharmaceutical Medical Executive with over 20 years of global experience specializing in metabolism, obesity, renal, and cardiovascular diseases. His career spans leadership roles across the United States and Europe, making him a central figure in international medical affairs.

Most recently, Dr. Verge served as the Head of Patient Safety and Medical Affairs at Zealand Pharma in Copenhagen. His previous executive tenures include Vice President of Global Medical Affairs for CV, Renal, and Metabolic diseases at AstraZeneca, and Vice President of Medical Affairs at Novo Nordisk US. He has played a crucial role in the development and launch of numerous innovative antidiabetic compounds, including pioneering work on insulin analogs and liraglutide.

Dr. Verge holds a Bachelor of Science from St. Lawrence University (USA), a medical degree from the University of Buenos Aires, and an MBA from the Copenhagen Business School (SIMI). He is an active member of both the American Diabetes Association and the European Association for the Study of Diabetes, and is a widely published expert in cardiovascular aspects of GLP-1R agonists.